Sign up Australia
Proactive Investors - Run By Investors For Investors

Pharmaxis strengthens balance sheet with $15 million milestone payment

The payment has unlocked the full deal potential of $625 million.
Laboratory tests
BI 1467335 is also being trialled for the treatment of liver disease NASH

Pharmaxis Ltd (ASX:PXS) has earned a $15 million payment as Boehringer Ingelheim has expanded its development plan for BI 1467335 to include treatment of blindness caused by diabetes.

Dosing of the first patient in Boehringer Ingelheim’s Phase 2a clinical trial in patients with diabetic retinopathy triggered the payment.

It is the second disease targeted by the drug developed by Pharmaxis, which is being used in a Phase 2a clinical trial for the chronic liver disease NASH (non‐alcoholic steatohepatitis).

The studies into NASH and diabetic retinopathy are due to report in the second half of 2018.

Today’s payment further strengthens the Pharmaxis balance sheet, which held $39 million in cash at the end of September 2017.

WATCH NOW: Pharmaxis' CEO Gary Phillips updates on partnership with Boehringer Ingelheim

Gary Phillips, chief executive officer, said: “This milestone payment marks the expansion of the Boehringer Ingelheim development plan for BI 1467335 into two diseases.

“All the potential development milestones in the $625 million deal would be payable to Pharmaxis should both indications be approved.

“Both development plans attract the same total development payments through to approval, with the second indication milestone payments weighted more towards approval.

“The next milestones from BI are payable if they choose to commence phase 3 trials, at which time the two indications would attract €62 million [circa $94 million] in milestones.”

A leading cause of vision loss

Diabetic retinopathy is the leading cause of vision loss in adults aged 20‐74.

Of an estimated 285 million people with diabetes mellitus worldwide, 33% have signs of the disease.  

The Phase 2a clinical trial of BI 1467335 in diabetic retinopathy will randomise 100 patients to drug or placebo for a 12‐week treatment period with an additional 12‐week follow‐up period.

After the study reports later this year, a subsequent Phase 2b study will seek to confirm and extend the findings.

Two-pronged clinical program

Boehringer Ingelheim’s two‐pronged clinical program with BI 1467335 is focused on tackling the common diseases related to the complications of diabetes which affect millions worldwide.

The drug was acquired by Boehringer Ingelheim in 2015 with an upfront payment of $41 million to initially study NASH.

Additional portfolio

Pharmaxis has a portfolio of products at various stages of development and approval.

Its product Bronchitol for cystic fibrosis is marketed in Europe, Russia and Australia.

READ: Pharmaxis secures further Australian government reimbursement for Bronchitol

Another product, Aridol, for the assessment of asthma, is sold in Europe, Australia and Asia.

The company’s development pipeline is centred on its expertise in amine oxidase chemistry.

It includes a series of Lysyl Oxidase Inhibitors that have entered clinical development targeting fibrotic diseases of the heart, kidney, liver and lung.

View full PXS profile View Profile

Pharmaxis Ltd Timeline

Related Articles

July 03 2018
The research and diagnostic company develops cancer-detecting blood tests
Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
Lung X-Ray
October 08 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use